Boston Scientific to Acquire Penumbra in $14.5 Billion Cash and Stock Transaction
Summary
Boston Scientific Corporation agreed to acquire Penumbra, Inc. in a cash and stock transaction valued at approximately $14.5 billion. Penumbra shareholders will receive $374 per share (73% cash, 27% Boston Scientific stock). The transaction includes approximately $11 billion in cash financed through a combination of cash on hand and new debt. Penumbra is a leading thrombectomy company with neurovascular offerings including stroke revascularization and neuro embolization devices.
Why it matters
This acquisition is the largest in Boston Scientific's history and provides scaled entry into mechanical thrombectomy and neurovascular markets. For neurotechnology broadly, it signals that large medtech strategics are willing to pay significant premiums for neurology device companies with innovative approaches to brain and vascular conditions.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial